Conciseness

The body is dense with non-redundant, database-specific guidance ('The parameter is `name` (NOT `query`)', 'Check `len(studies) > 0` rather than `total_count`'), but includes trimmable over-explanation: basic inheritance-mode genetics Claude already knows ('Autosomal recessive: need TWO hits (homozygous or compound heterozygous)') and a chatty multi-clause aside on deep intronic variants ("but 'usually' is doing real work"). This matches 'efficient; minor instances of over-explanation that could be trimmed' rather than 5, whose every-token-earns-its-place bar the padded asides miss, and rather than 3, since the over-explanation is minor relative to the parameter-level detail Claude cannot know.

Actionability

Every tool has exact required parameters and types ('Orphanet_get_disease: `orpha_code` (string REQUIRED, e.g., "558")') and the example workflows give concrete calls ('Orphanet_search_diseases(name="Marfan syndrome") -> ORPHAcode 558'), but the workflows use `->` shorthand rather than copy-paste code and no runnable Python analysis example appears despite the 'COMPUTE, DON'T DESCRIBE' directive. This is 'mostly executable guidance with minor gaps' — not 5 (not fully copy-paste ready), not 3 (the tool calls are concrete and specific, not pseudocode).

Workflow Clarity

Phases 0-9 are explicitly sequenced with an ordering rule ('phenotype -> disease -> gene -> variant, not the reverse'), evidence-grading tiers, a completeness checklist, and a fallback/error-recovery section. It falls short of 5 because one fallback bullet is self-referential and incoherent ('Disease lookup: try `Orphanet_search_diseases` if `Orphanet_search_diseases` fails') and per-phase exit criteria are sometimes implicit; it is above 3 because the checklist, tiering, and fallbacks provide real validation checkpoints. The destructive/batch cap does not apply — this is read-only research orchestration.

Progressive Disclosure

No bundle files exist (no references/, scripts/, or assets/ directories), so the entire ~280-line per-tool API reference is inlined in SKILL.md and loads on every invocation. Section headers are clear (one section per phase), which keeps it above 2 ('minimal structure'), but bulk parameter reference that clearly belongs in a separate reference file is inline with no one-level-deep pointers, matching 'some structure... content that should be separate is inline' rather than 4.

Specificity

The description lists five concrete capabilities each anchored to a named resource — 'disease identification (Orphanet), causative gene discovery, gene-disease validity (GenCC), variant interpretation (ClinVar), and translational research (ClinicalTrials.gov, drug repurposing for orphans)' — which matches 'lists multiple specific concrete actions; comprehensive coverage'. It is not 4: the enumeration spans the full workflow from disease to drug development with no notable coverage gap, and all actions are concrete rather than generic.

Completeness

Both parts are explicit: a clear 'what' (five enumerated capabilities) and an explicit when-clause ('Use for rare-disease-gene curation, novel-gene-discovery analysis, and rare-disease drug-development support'). It falls just short of 5 because the trigger phrases are formal compound terms rather than the concrete, natural user phrasings the top anchor requires ('when the user mentions PDFs, forms, or document extraction'), and is clearly above 3 since the when-guidance is explicit, not merely implied.

Trigger Term Quality

Natural terms like 'rare disease', 'variant interpretation', and 'drug repurposing' are present, but the when-clause leans on compound jargon ('rare-disease-gene curation, novel-gene-discovery analysis') rather than phrases users naturally say, and common synonyms ('orphan disease', 'inherited disorder', 'genetic disorder') are absent from the description. This sits between anchor 3 and anchor 5, landing at 'good keyword coverage; a few natural terms missing' — not 5 because synonyms and natural user phrasings are missing, not 3 because genuinely natural keywords are included.

Distinctiveness Conflict Risk

The description carves a clear niche via named resources (Orphanet, GenCC, ClinVar) and scoping to rare disease, matching 'mostly distinct; minor overlap risk with closely related skills'. It is not 5 because the skill family it belongs to has close siblings (differential diagnosis, pharmacogenomics, cancer variant interpretation) whose territory shares terms like 'variant interpretation' and 'gene-disease', and not 3 because the rare-disease genomics niche and its database anchors are unmistakable.